New FDA guid­ance gives man­u­fac­tur­ers lim­its for ni­trosamines

Af­ter as­sess­ing com­ments from in­dus­try play­ers, the FDA has fi­nal­ly is­sued its fi­nal guid­ance with rec­om­men­da­tions on ac­cept­able in­take lim­its for ni­trosamine im­pu­ri­ties in drugs.

The 24-page guid­ance pub­lished Fri­day delves in­to the top­ic of ni­trosamine drug sub­stance-re­lat­ed im­pu­ri­ties, or ND­SRIs, which can cause can­cer. And com­pa­nies have un­til Nov. 1 to com­plete some as­sess­ments, with the FDA ex­plain­ing:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER